title: Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.
authors.affiliation: Eye Clinic Sulzbach, Knappschaftsklinikum Saar, Sulzbach, 66280 , Germany.
authors.forename: Gesine B
authors.initials: GB
authors.lastname: Szurman
authors.affiliation: Department of Ophthalmology, Pallace Clinics, Aarau, Switzerland.
authors.forename: Carsten H
authors.initials: CH
authors.lastname: Meyer
authors.affiliation: University Eye Hospital, University of Goettingen, Goettingen, Germany.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Feltgen
authors.affiliation: Hannover Medical School, University Eye Hospital, Munich, Germany.
authors.forename: Amelie
authors.initials: A
authors.lastname: Pielen
authors.affiliation: Department of Neurology and Bernstein Center for Computational Neuroscience, Charité, Berlin, Germany.
authors.forename: Bernhard
authors.initials: B
authors.lastname: Spitzer
authors.affiliation: University Eye Hospital, University of Leipzig, Leipzig, Germany.
authors.forename: Matus
authors.initials: M
authors.lastname: Rehak
authors.affiliation: Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Spital
authors.affiliation: Centre for Ophthalmology, University Eye Clinic Tuebingen, Tuebingen, Germany.
authors.forename: Spyridon
authors.initials: S
authors.lastname: Dimopoulos
authors.affiliation: Eye Clinic Sulzbach, Knappschaftsklinikum Saar, Sulzbach, 66280 , Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Szurman
authors.affiliation: Eye Clinic Sulzbach, Knappschaftsklinikum Saar, Sulzbach, 66280 , Germany. Kai.januschowski@med.uni-tuebingen.de.|Centre for Ophthalmology, University Eye Clinic Tuebingen, Tuebingen, Germany. Kai.januschowski@med.uni-tuebingen.de.
authors.forename: Kai
authors.initials: K
authors.lastname: Januschowski
mesh_terms: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema; D012170:Retinal Vein Occlusion; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab